Plain-English translation of NCT06199713 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Melanoma research guide →This research study is testing whether two types of early monitoring—special imaging scans called PET/CT scans and blood tests that measure tumor DNA—can predict how well immune checkpoint inhibitor medications (like ipilimumab, nivolumab, and pembrolizumab) are working in people with advanced melanoma. The study wants to see if these early signals can help doctors know within the first 3-4 weeks whether the medication will be effective and whether side effects might develop.
Currently, doctors often have to wait weeks or months to see if this treatment is working. This trial aims to find faster, earlier ways to predict treatment success and catch potential problems sooner, so doctors can make better decisions about your care.
You likely qualify if…
You likely don't qualify if…
You would receive your planned melanoma treatment as normal, but with additional monitoring. At baseline and again 3-4 weeks after starting treatment, you'll have a special PET/CT imaging scan and blood draws to measure tumor DNA. The study team will track how these early results relate to how well your treatment works and any side effects you experience over time. The study involves about 24 patients total and follows participants for the duration of their treatment.
AI-generated summary from trial data · Jun 9, 2026 · Not medical advice
United States